Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT06970665 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT06970665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06970665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 8, 2025
Completion date
June 30, 2027
Enrollment
17 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, geographic atrophy